Nektar Therapeutics
NKTR
124 hedge funds and large institutions have $106M invested in Nektar Therapeutics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 50 reducing their positions, and 17 closing their positions.
5,513% more call options, than puts
Call options by funds: $449K | Put options by funds: $8K
57% more capital invested
Capital invested by funds: $67.4M → $106M (+$38.2M)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1% less funds holding
Funds holding: 125 → 124 (-1)
0.96% less ownership
Funds ownership: 62.5% → 61.55% (-0.96%)
60% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$2.79M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.43M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.73M |
| 4 |
SC
Shay Capital
New York
|
+$1.45M |
| 5 |
Millennium Management
New York
|
+$969K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$2.28M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.71M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.7M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.33M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.08M |
NKTR Hedge Fund Activity: Q1 2024 in Review
124 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2024, worth a combined $106M — up 57% from $67.4M a quarter earlier.
Fund positioning in NKTR was balanced in Q1 2024: 17 funds opened new positions, 17 closed out, 20 added to existing stakes and 50 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $2.79M. The largest seller was GSA Capital Partners, cutting an estimated $2.28M.
- 124 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2024, down from 125 in Q4 2023.
- Funds reported $106M of Nektar Therapeutics stock for Q1 2024, up 57% quarter-over-quarter.
- 17 funds opened new Nektar Therapeutics positions in Q1 2024 and 17 closed out, a net change of 0 holders.
- The largest Nektar Therapeutics buyer in Q1 2024 was TCG Crossover Management, an estimated $2.79M added.
- The largest Nektar Therapeutics seller in Q1 2024 was GSA Capital Partners, an estimated $2.28M sold.
Based on aggregated 13F filings for Q1 2024.